Who founded Alentis Therapeutics?

Alentis Therapeutics was founded by Thomas Baumert in 2019.

Who are Alentis Therapeutics's investors?

Alentis Therapeutics's investors include Avego BioScience Capital, BioMedPartners, Frazier Life Sciences, Jeito Capital, Longitude Capital, Novo Holdings, OrbiMed, RA Capital and 4 more.

Where is Alentis Therapeutics headquartered?

Alentis Therapeutics is headquartered in Basel, CH.

Alentis Therapeutics

Basel, CH · Founded 2019 · 70 employees on LinkedIn · 12 known investors

Find your way into Alentis Therapeutics

238 people in our graph share verified history with the Alentis Therapeutics team — schools, employers, funds. One of them is your warm intro.

Cristina Ghenoiuunlockedknows Thomas Baumert · together at Universitätsklinikum Freiburg (overlapped)

×3knows the team · via HiFiBiO Therapeutics

×3knows the team · via Novartis Oncology

×3knows the team · via Alentis

×2knows the team · via Université de Strasbourg

Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease. It operates as a clinical-stage biopharmaceutical company advancing small molecules, antibodies, and related drug programs in oncology and fibrotic diseases.

AI & Machine Learning Biotech Healthtech Medical Devices

Founders & leadership

Alentis Therapeutics was founded in 2019 by Thomas Baumert.

Thomas Baumert FounderThomas Baumert holds an MD from the University of Heidelberg and completed training in internal medicine and gastroenterology at Ludwig Maximilians University Munich and the University Hospital Freiburg. He served as a fellow at Harvard Medical School and the NIH Liver Diseases Branch, became an associate professor in Freiburg, and is currently a professor of medicine at the University of Strasbourg and director of the Inserm Institute for Translational Medicine, with research focused on fibrosis and cancer therapies; he founded Alentis Therapeutics.

Mark PruzanskiChief Executive OfficerChief Executive Officer at Alentis

Luigi Manenti Chief Medical OfficerLuigi Manenti is Chief Medical Officer at Alentis Therapeutics, a clinical-stage biotech company developing therapies for liver disease and cancer. He holds an MD in Medicine from Università di Pavia and has held senior leadership roles in clinical development and oncology at Roche, Novartis, and HiFiBiO Therapeutics, where he worked on antibody discovery and immuno-oncology programs.

Jon FreveChief Financial OfficerChief Financial Officer at Alentis

Bryan YoonGeneral Counsel and Chief Administrative OfficerExecutive Officer at Terns Pharmaceuticals

Aditya VenugopalChief Business OfficerChief Business Officer at Alentis

Alberto TosoChief Scientific OfficerChief Scientific Officer at Alentis

Roberta MarchioneChief Technology OfficerChief Technology Officer at Alentis

Investors · 12

Avego BioScience Capital✓ confirmed by Alentis TherapeuticsAlpharetta

How we know: Avego BioScience Capital's portfolio page · the company's own site · Not right? Tell us

BioMedPartners✓ confirmed by Alentis TherapeuticsBasel · $648K – $6.5M

How we know: BioMedPartners's portfolio page · the company's own site · the VCSheet dataset · Not right? Tell us

Frazier Life Sciences✓ confirmed by Alentis TherapeuticsPalo Alto

How we know: the company's own site · Frazier Life Sciences's portfolio page · Not right? Tell us

Jeito Capital✓ confirmed by Alentis TherapeuticsParis

How we know: Jeito Capital's portfolio page · the company's own site · Not right? Tell us

Longitude Capital✓ confirmed by Alentis TherapeuticsMenlo Park · $10M – $30M

How we know: the company's own site · Longitude Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Novo Holdings✓ confirmed by Alentis TherapeuticsCopenhagen · $1.1M – $54M

How we know: Novo Holdings's portfolio page · the company's own site · Not right? Tell us

OrbiMed✓ confirmed by Alentis TherapeuticsNew York · $1M – $75M

How we know: OrbiMed's portfolio page · the company's own site · funding news · the VCSheet dataset · Not right? Tell us

RA Capital✓ confirmed by Alentis TherapeuticsBoston

How we know: RA Capital's portfolio page · the company's own site · Not right? Tell us

Bpifrance✓ confirmed by Alentis TherapeuticsParis, Ile-De-France · $270K

How we know: the company's own site · Not right? Tell us

Catalio Capital Management✓ confirmed by Alentis TherapeuticsNew York

How we know: the company's own site · Not right? Tell us

Catalio Capital Management, LPlisted by Catalio Capital Management, LPNew York

How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us

Pureos Bioventureslisted by Pureos BioventuresPfäffikon

How we know: Pureos Bioventures's portfolio page · Not right? Tell us

In the news

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors - Alentis Therapeuticsalentis.ch · Nov 2024

Investors - Alentis Therapeuticsalentis.ch · Jul 2020

News - Alentis Therapeuticsalentis.ch · Apr 2019

Frequently asked questions

What does Alentis Therapeutics do?: Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease. It operates as a clinical-stage biopharmaceutical company advancing small molecules, antibodies, and related drug programs in oncology and fibrotic diseases.
Who founded Alentis Therapeutics?: Alentis Therapeutics was founded by Thomas Baumert in 2019.
Who are Alentis Therapeutics's investors?: Alentis Therapeutics's investors include Avego BioScience Capital, BioMedPartners, Frazier Life Sciences, Jeito Capital, Longitude Capital, Novo Holdings, OrbiMed, RA Capital and 4 more.
Where is Alentis Therapeutics headquartered?: Alentis Therapeutics is headquartered in Basel, CH.